en · de · es · fr · pt
aod-9604-notes.peptides6579.com › Guide › Research And Regulatory Status — Worked Examples

Research And Regulatory Status — Worked Examples

By Editorial Desk · published 2026-02-11 · last reviewed 2026-03-30 · Guide

This is a working overview of obesity research, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-03-30 and is reviewed periodically as new material appears.

Research and Regulatory Status

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

Mechanism And Metabolic Effects

Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.

Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.

Aod-9604 at a glance

PropertyValueNotes
Primary research areaObesity and metabolic regulationStudied in cell, animal, and human models
Highest reported trial phasePhase IIPublic summaries describe mixed results
Common route in trialsSubcutaneous injectionTypical for peptide therapeutics
Regulatory example2013 Australian anti-doping reviewClassification was debated at the time
Approval statusNot approved as a human medicineStatus can change by jurisdiction

Handling, Analysis, and Quality Control

AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.

Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.

Related pages on this site

Measurement and Storage Practices

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Reference notes

=== Cell Biology and Virology === Organised into subprograms including Eukaryotic Microbiology, Tumor Cell Biology, Virology, and Mammalian Cell Structure/Differentiation, this program studies cellular functions across organisms. Research areas include tumor-virus associations, host-pathogen signaling, gene therapy, and vaccine development.

Blixeprodil, also known by its developmental code name GM-1020 or as (R)-4-fluorodeschloroketamine ((R)-4-FDCK), is an NMDA receptor antagonist related to ketamine which is under development for the treatment of major depressive disorder, bipolar depression, and other depressive disorders. It is taken by mouth.

4 September – Mick Molloy, 85, Olympic long-distance runner (1968). 6 September – Dermot Keogh, 78, historian and author. 8 September – John Kelly, 78, hurler (Cappawhite, Kilruane MacDonaghs, Tipperary senior team, Munster). 19 September Jimmy Brohan, 88, hurler (Blackrock, Cork senior team, Munster). Brendan Devlin, 92, academic. Rónán Mac Aodha Bhuí, 53, broadcaster. 28 September – Michael Gambon, 82, Irish-English actor (Harry Potter, Gosford Park, The King's Speech), pneumonia.

Sources: en.wikipedia.org

Notes from published material

The metal is produced electrolytically from a mixture of fused lithium chloride and potassium chloride. Sodium occurs mostly in seawater and dried seabed, but is now produced through electrolysis of sodium chloride by lowering the melting point of the substance to below 700 °C through the use of a Downs cell. Extremely pure sodium can be produced through the thermal decomposition of sodium azide. Potassium occurs in many minerals, such as sylvite (potassium chloride). Previously, potassium was generally made from the electrolysis of potassium chloride or potassium hydroxide, found extensively in places such as Canada, Russia, Belarus, Germany, Israel, United States, and Jordan, in a method similar to how sodium was produced in the late 1800s and early 1900s. It can also be produced from seawater. However, these methods are problematic because the potassium metal tends to dissolve in its molten chloride and vaporises significantly at the operating temperatures, potentially forming the explosive superoxide. As a result, pure potassium metal is now produced by reducing molten potassium chloride with sodium metal at 850 °C.

=== Switzerland === In Switzerland, the sale and production of absinthe was prohibited from 1910 to 1 March 2005. This was based on a vote in 1908, inspired by the Jean Lanfray incident. To be legally made or sold in Switzerland, absinthe must be distilled, must not contain certain additives, and must be either naturally coloured or left uncoloured. In 2014, the Federal Administrative Court of Switzerland invalidated a governmental decision of 2010 which allowed only absinthe made in the Val-de-Travers region to be labelled as absinthe in Switzerland. The court found that absinthe was a label for a product and was not tied to a geographic origin.

== Immune difficulties for the cornea == The most important function of the cornea is to transmit and refract light so as to allow sharp (high-resolution) images to be produced on the back of the retina. To do this, collagen within the cornea is highly ordered to be 30 nanometers in diameter and placed 60 nanometers apart so as to reduce light scatter. Furthermore, the tissue is not vascularized, and does not contain lymphoid cells or other defense mechanisms, apart from some dendritic cells (DC). Both of these factors necessitate the small number of cells within the cornea. However, this necessitates keeping immune cells at a relative distance, effectively creating a time delay between exposures to a pathogen and mounting of an immune response. Therefore, many immune and protective responses within the cornea, such as moistening and nutrition, come from non-local sources, such as the conjunctiva.

Sources: en.wikipedia.org

Background from the literature

Eggshells, snail shells and most seashells are predominantly calcium carbonate and can be used as industrial sources of that chemical. Oyster shells have experienced recognition as a source of dietary calcium since the early 2010s, but also remain a practical industrial source. Dark green vegetables such as broccoli and kale contain dietarily significant amounts of calcium carbonate, but they not practical as an industrial source. Annelids in the family Lumbricidae, earthworms, possess a regionalization of the digestive track called calciferous glands, Kalkdrüsen, or glandes de Morren, that processes calcium and CO2 into calcium carbonate, which is later excreted into the dirt. The function of these glands is unknown but is believed to serve as a CO2 regulation mechanism within the animals' tissues. This process is ecologically significant, stabilizing the pH of acid soils.

After this period, they are able to advance to registrar grade when they undergo a compulsory subspecialty training (including acute internal medicine or a dual subspecialty including internal medicine). This latter stage of training is achieved through competition rather than just by yearly progress as the first years of postgraduate training.

The mass spectrometer is capable of multicollection, meaning up to 5 (NanoSIMS 50) or 7 (NanoSIMS 50 L) masses can be simultaneously detected, from hydrogen to uranium, though with limitations. The relatively large number of masses helps eliminate measurement errors as possible changes in instrumental or sample conditions that may occur in between runs are avoided. The ion beam must either be set to detect negative or positive ions, commonly completed by using a cesium+ or oxygen- beam, respectively. The high mass resolution achievable is particularly relevant to biological applications. For example, nitrogen is one of the most common elements in organisms. However, due to the low electron affinity of the nitrogen atom, the production of secondary ions is rare. Instead, molecules such as CN can be generated and measured. However, due to isotope combinations, such as the isobars 13C14N-, and 12C15N-, nearly identical molecular weights of 27.000 and 27.006 daltons, respectively, will be generated. Unlike other imaging techniques, where 13C14N and 12C15N cannot be independently measured due to nearly identical masses, NanoSIMS can safely distinguish the differences between these molecules allowing isotopic spiking experiments to be conducted.

Sources: en.wikipedia.org

Frequently asked questions

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Why is AOD-9604 discussed in anti-doping?

It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.

What did human trials of AOD-9604 find?

Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.

How is AOD-9604 thought to work?

It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.

Network